AGXT and asthma: With perhaps one exception (26), ORMDL3-dependent SPT regulation has been demonstrated in many cell types over several different studies (14–20), presenting a reasonable hypothesis that sphingolipid dysregulation could contribute to asthma pathophysiology in patients with the 17q12–21 risk SNPs.